PDCD1 and hepatocellular carcinoma: In recent years, molecular and immune-targeted therapies such as Lenvatinib, programmed cell death protein 1 (PD-1) monoclonal antibodies, and bevacizumab have achieved good results in HCC; however, they still face problems such as high cost, poor targeting, and adverse reactions [4, 5].